Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
The proposer is required to obtain funding from either the private sector, a non-SBIR Government source, or both, to develop the prototype software into a viable product or non-R&D service for sale in military or private sector markets
Start your intake How GLP-1s May Affect Mood and Mental Health GLP-1 receptor agonists activate receptors in brain regions associated with reward, stress response, and appetite regulation
Chao AM, Jastreboff AM, White MA, Grilo CM, Sinha R
Coordinate care between specialists
Read more Discover why Zepbound quiets constant food thoughts and helps you regain control of your eating habits